| 摘要 |
The invention provides a method for determining the efficacy of a TNFalpha inhibitor, such as a TNFalpha antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.
|
